|CCL 23.03.02 Cresset Webinar: Australian Program for Drug Repurposing for Treatment Resistant Ovarian Cancer|
From: chemistry-request at ccl.net
To: chemistry-request at ccl.net
Date: Wed Feb 22 05:54:35 2023
Subject: 23.03.02 Cresset Webinar: Australian Program for Drug Repurposing for Treatment Resistant Ovarian Cancer
Date: Thursday 2nd March, 2023 Time: 3pm CET / 2pm GMT / 9am EST Duration: 45 minutes Format: Webinar REGISTER HERE: https://www.cresset-group.com/about/events/treatment-resistant-ovarian-cancer/ We look forward to welcoming Professor Nikola Bowden, University of Newcastle to host this upcoming webinar with Dr Martin Slater, Director of Discovery, Cresset. High grade serous (HGS) ovarian cancer is the most common subtype of ovarian cancer and has a poor 5-year survival rate due to disease recurrence and resistance to current therapies. Effective new therapies are urgently required. Ongoing efforts to find new drug targets are continuing, but traditional drug development requires approximately 12-16 years processing time and investment of USD$1-2 billion to achieve market approval. This lengthy development pipeline, while necessary for identifying innovative treatments, is not the only option for providing patients with timely access to efficacious, cost-effective therapy. Drug repurposing is a method for identifying new uses for approved or investigational drugs that are outside the scope of the original intended or approved medical use. The development of repurposed drugs is attractive because therapeutic advances and new drug options for ovarian cancer patients has been far slower than expected. The Australian program for drug repurposing for treatment resistant ovarian cancer is working with Cresset Discovery to screen Federal Drug Administration (FDA) and European Medicines Agency (EMA) approved drugs for potential interaction with well-defined 'druggable' targets specific to ovarian cancer. This is a world first large-scale program of drug repurposing for ovarian cancer. Over the 5-years of this program we aim to screen 20 drug targets/biological pathways, identified as targets for treatment-resistant HGS ovarian cancer. REGISTER HERE: https://www.cresset-group.com/about/events/treatment-resistant-ovarian-cancer/NOTE THAT E-MAIL ADDRESSES HAVE BEEN MODIFIED!!!
All @ signs were changed to -,- to fight spam. Before you send e-mail, you need to change -,- to @
For example: change joe-,-big123comp.com to email@example.com
Please let colleagues know about conference listingts at Computational Chemistry List Conference Page at http://www.ccl.net/chemistry/a/conferences/.
Please help: If you find this conference list useful but you noticed some conference missing, please consider including it here by using the Conference Submission Page. It is free but your support is welcome. You will help others!!!
|Modified: Wed Feb 22 10:54:35 2023 GMT|
|Page accessed 718 times since Wed Feb 22 10:53:06 2023 GMT|
Please help maintain CCL: If you found that your conference is listed here, please consider supporting CCL as a Supporting Member or use other Paid Services of CCL to ensure the continuation of this useful service. We cannot do it without your help.